Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06900010 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate CM336 in Adults With Autoimmune Bullous Disease

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Phase: Phase 1/2 to Phase 2v2 Show 4 more changesShow less
    • Primary completion date: Jan 1, 2026 to Jan 1, 2027
    • Study completion date: Jan 1, 2027 to Jan 1, 2028
    • Start date changed from estimate of Apr 1, 2025 to Apr 22, 2025
    • Study description expanded, about 96 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults with Moderate to Severe Autoimmune Bullous Disease
Trial Details
NCT Number NCT06900010
Lead Sponsor Shandong First Medical University
Conditions
(from sponsor)		 Autoimmune Bullous Disease
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov